Drug for opioid-induced constipation (OIC) treatment. The portfolio consists of the rights to sell and develop Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein.
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore AstraZeneca (Moventig)‘s full profile, request access.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore AstraZeneca (Moventig)‘s full profile, request access.
Request a free trial